Royalty Pharma PLC
(NAS:RPRX)
$
26.6
0.31 (1.18%)
Market Cap: 11.82 Bil
Enterprise Value: 17.66 Bil
PE Ratio: 10.43
PB Ratio: 1.73
GF Score: 79/100 Royalty Pharma PLC at UBS Global Healthcare Conference Transcript
May 24, 2022 / 05:15PM GMT
Release Date Price:
$39.74
(-0.77%)
Colin Bristow
Good afternoon, everyone, and thank you for attending the UBS Global Healthcare Conference. I'm Colin Bristow, one of the biotech analysts here. It is my pleasure to have with us today, Royalty Pharma. From Royalty, we have Marshall Urist, EVP and Co-Head of Research and Investments; and Chris Hite, EVP and Vice Chairman. Thank you for joining us today.
Christopher Hite
Royalty Pharma plc - Executive VP & Vice Chairman
Thank you.
Marshall Urist
Royalty Pharma plc - Executive VP and Head of Research & Investments
Thanks, Colin.
Colin Bristow
(Operator Instructions) There we go. So I know you have some opening remarks. So I'll let you take it away, and then we'll dig into some of the questions.
Christopher Hite
Royalty Pharma plc - Executive VP & Vice Chairman
Okay. Great. I think Marshall and I will do a quick spin through some slides and then obviously open up to Q&A. So -- but thank you very much for
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot